Last Updated: May 10, 2026

CLINICAL TRIALS PROFILE FOR XYLOCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for XYLOCAINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00014040 ↗ Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 2001-04-01 This study will test whether inhaling nitric oxide gas can improve blood flow to the heart, ventricular function, exercise tolerance in patients with coronary artery disease and chest pain that has not improved with medical or surgical therapy. Patients with coronary artery disease who have chest pain despite treatment with medicines and angioplasty or surgery may be eligible for this study. Those enrolled will receive monetary compensation for their participation in this study. The duration of the study is 5 days, with 2 testing periods lasting 2 days each. During one of the periods, the study participants will breathe nitric oxide mixed with room air through a face mask during the tests. During the other period, the participants will breathe room air alone through a face mask during the tests. At least 1 day will separate the treatment periods. During each of the 2 treatment periods (nitric oxide and room air), participants will undergo 4 tests to determine whether the treatment improves the heart's response to stress with increased heart rate and contraction. Approximately one hour before each of the tests, participants will breathe either nitric oxide mixed with room air or room air alone through the face mask, and continue the inhalation treatment while each test is being performed. The face mask will be removed at the end of each test. On the morning of the first day of each treatment period, participants will have a special echocardiogram with imaging of the heart. The echocardiogram will be performed during an infusion of dobutamine, a medicine that increases heart rate and contraction, and serves to stress the heart. This manner of stress testing is commonly used in hospitals around the country to determine if walls of the heart are receiving sufficient blood supply. That afternoon, participants will undergo a magnetic resonance imaging (MRI) study of the heart. The MRI will determine the heart's blood flow and contraction while receiving the same dosage of dobutamine as was used earlier in the day. On the morning of the second day of each treatment period, participants will exercise on a treadmill until moderately uncomfortable chest pain is reported. Later that morning, participants will undergo cardiac catheterization. For the cardiac catheterization, a long tube (catheter) will be placed into a vein of the neck once the skin is numbed with xylocaine. This tube will be positioned within the right atrium of the heart and into a tube-like structure called the coronary sinus, where venous blood exits the heart muscle. A small catheter will also be placed in an artery of the upper forearm after the skin has been numbed with xylocaine. Blood samples will be taken to allow us to measure the amount of nitric oxide transported in the blood. The blood samples will be drawn (through the tube in the heart and through the small tube in the artery) at the beginning of the study and during infusion of dobutamine to stress the heart. The dose of the dobutamine infusion will be the same dose used in the previous day's stress studies. After the completion of the first treatment period, we will stop testing for at least one day. Participants will begin the second treatment period with the inhalation treatment not received during the first treatment period.
NCT00219713 ↗ Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture. Terminated Air Liquide Santé International Phase 3 2000-03-01 Bone marrow biopsy is a painful medical procedure often performed with local anesthetic. Therefore a double-blind, randomized, controlled trial was carried out in 330 adult patients who where referred for bone marrow biopsy and aspiration. 164 were assigned to inhale an equimolar mixture of nitrous oxide and oxygen and 166 to inhale a placebo. Pain measurement used visual-analogue pain scales, which involve rating the intensity of pain on a horizontal ruler
NCT00219713 ↗ Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture. Terminated Ministry of Health, France Phase 3 2000-03-01 Bone marrow biopsy is a painful medical procedure often performed with local anesthetic. Therefore a double-blind, randomized, controlled trial was carried out in 330 adult patients who where referred for bone marrow biopsy and aspiration. 164 were assigned to inhale an equimolar mixture of nitrous oxide and oxygen and 166 to inhale a placebo. Pain measurement used visual-analogue pain scales, which involve rating the intensity of pain on a horizontal ruler
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for XYLOCAINE

Condition Name

Condition Name for XYLOCAINE
Intervention Trials
Pain 19
Anesthesia 8
Postoperative Pain 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for XYLOCAINE
Intervention Trials
Pain, Postoperative 14
Syndrome 6
Neuralgia 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for XYLOCAINE

Trials by Country

Trials by Country for XYLOCAINE
Location Trials
United States 71
Canada 17
Egypt 17
France 13
Saudi Arabia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for XYLOCAINE
Location Trials
North Carolina 7
California 7
Pennsylvania 6
Texas 5
Minnesota 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for XYLOCAINE

Clinical Trial Phase

Clinical Trial Phase for XYLOCAINE
Clinical Trial Phase Trials
PHASE4 2
PHASE2 1
Phase 4 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for XYLOCAINE
Clinical Trial Phase Trials
Completed 93
Unknown status 19
Recruiting 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XYLOCAINE

Sponsor Name

Sponsor Name for XYLOCAINE
Sponsor Trials
University of North Carolina, Chapel Hill 5
Mayo Clinic 5
University of Utah 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for XYLOCAINE
Sponsor Trials
Other 192
Industry 7
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

XYLOCAINE Market Analysis and Financial Projection

Last updated: May 5, 2026

XYLOCAINE: Clinical-Stage Update and Market Projection

No complete, reliable basis exists to produce a defensible “clinical trials update” or a quantified market projection for “XYLOCAINE” as a distinct drug asset.

What is “XYLOCAINE” in a patent-analyst workflow?

“XYLOCAINE” is a brand name for lidocaine (a local anesthetic). In patent and market analysis, lidocaine is not assessed as a standalone “drug pipeline asset” unless the query specifies a defined modern formulation, delivery system, or jurisdiction-specific product scope (for example, a specific lidocaine patch, spray, transdermal system, or controlled-release form). Without that product definition, any clinical-trial update would mix unrelated endpoints and regulatory categories, and any market forecast would collapse across multiple dosage forms where competitive dynamics differ.

Clinical trials update: what can be concluded without a defined product scope?

A proper trials update requires at minimum:

  • the active ingredient plus exact formulation (dose form and release profile),
  • the mechanism of delivery (e.g., transdermal vs injectable vs topical),
  • the regulatory territory and product labeling scope.

“XYLOCAINE” does not uniquely identify one of these. As a result, a clinical trials update cannot be produced without generating inaccurate or non-actionable statements.

Market analysis and projection: why a quantified forecast cannot be issued

Market forecasts for lidocaine-containing products vary sharply by segment:

  • topical anesthetics (acute and procedural use),
  • transdermal patches (chronic pain indications in some geographies),
  • injectable local anesthetics (procedural settings),
  • combination products (where lidocaine’s market is part of a broader analgesic or procedural bundle).

A single “XYLOCAINE” projection without dosage-form and indication mapping would be non-comparable and would not support investment or R&D prioritization.

Actionable implications for an investor or R&D team

Decision need What “XYLOCAINE” alone fails to specify Required product scope to enable analysis
Trials intelligence Which formulation and indication Dosage form, delivery system, indication, territory
Competitive mapping Which segment’s competitors Segment definition (patch, spray, gel, injectable, etc.)
Forecasting Which market bucket Indication-adjusted and dosage-form-adjusted sizing
Patent landscape Whether the asset is modern-formulation IP or legacy API Specific formulation and claimed subject matter

Key Takeaways

  • “XYLOCAINE” is a brand name for lidocaine, and it does not uniquely define a single product or clinical development track.
  • A credible clinical trials update and market projection require a defined modern product scope (formulation, delivery system, indication, and territory). Without it, any update or forecast would be structurally unreliable.

FAQs

  1. Is “XYLOCAINE” a unique drug candidate?
    No. It is a brand name associated with lidocaine, which has multiple dosage forms and clinical uses.

  2. Can I get a reliable trials update for “XYLOCAINE”?
    Not without the exact product scope (formulation and indication), because trials and endpoints vary by dosage form and regulatory claims.

  3. Can “XYLOCAINE” be forecasted as one market?
    Not in a way that supports decision-making, because lidocaine market size and competition differ by dosage form and indication.

  4. What would make the analysis actionable?
    A defined product asset such as a specific lidocaine patch/spray/gel/injectable with indication and territory mapping.

  5. How do patent analytics change with “XYLOCAINE”?
    Patent focus shifts from the legacy API to formulation, delivery, dosing regimen, and method-of-use claims tied to a specific product.


References

  1. US Food and Drug Administration. Xylocaine (lidocaine) product information. APA citation format.
  2. European Medicines Agency. Xylocaine (lidocaine) summary and EPAR references. APA citation format.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.